Kidney transplant recipients vaccinated before transplantation maintain superior humoral response to SARS‐CoV‐2 vaccine

Majority of transplant recipients did not develop an appreciable humoral response following SARS‐CoV‐2 vaccine, in contrast to dialysis patients and healthy individuals. We analyzed the serologic response to BNT162b2 (Pfizer‐BioNTech) vaccine in a cohort of 19 kidney transplant recipients, vaccinated prior to transplantation, compare to 109 recipients vaccinated after transplantation, and to 39 healthcare workers, by determining the level of anti‐spike antibodies after transplantation. All controls and 17 of 19 (90%) of recipients vaccinated before transplant were seropositive, while only 49 of 109 (45%) recipients vaccinated post‐transplant had positive serology (P